2021
DOI: 10.1177/15459683211019362
|View full text |Cite
|
Sign up to set email alerts
|

Multidimensional Phase I Dose Ranging Trials for Stroke Recovery Interventions: Key Challenges and How to Address Them

Abstract: Despite an increase in the amount of published stroke recovery research, interventions have failed to markedly affect the trajectory of recovery poststroke. We argue that early-phase research to systematically investigate dose is an important contributor to advance the science underpinning stroke recovery. In this article, we aim to ( a) define the problem of insufficient use of a systematic approach to early-phase, multidimensional dose articulation research and ( b) propose a solution that applies this appro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 61 publications
(151 reference statements)
0
5
0
Order By: Relevance
“…This suggest that in addition to being individually tailored according to the level of the participants’ skills, the ACT-ING program should also emphasize individualization of duration and frequency for effective promotion of adherence [ 49 ]. Therefore, there is a need for further research on the most optimal intervention dose (i.e., duration, number of sessions, session length and density, and task length, difficulty, and intensity) within the resources available and how optimal dosing is influenced by factors such as age, sex, comorbidities, primary etiology, or physical fitness [ 10 , 51 ].…”
Section: Discussionmentioning
confidence: 99%
“…This suggest that in addition to being individually tailored according to the level of the participants’ skills, the ACT-ING program should also emphasize individualization of duration and frequency for effective promotion of adherence [ 49 ]. Therefore, there is a need for further research on the most optimal intervention dose (i.e., duration, number of sessions, session length and density, and task length, difficulty, and intensity) within the resources available and how optimal dosing is influenced by factors such as age, sex, comorbidities, primary etiology, or physical fitness [ 10 , 51 ].…”
Section: Discussionmentioning
confidence: 99%
“…Effects or markers that are presumably related to the intervention and that either are considered unacceptable or show the desired level of effect has been achieved and a further increase in dose is not required. 8…”
Section: Dose Limiting Criteriamentioning
confidence: 99%
“…2 also highlights an important aspect of why measurement and evaluation of active ingredients is critical. Rather than serve as "post-hoc" explanations of findings, addressing these issues in earlyphase pre-clinical trial stage can help narrow down the optimal decision at the end of a trial 24 . For example, if the active ingredient changed but there was no effect on overall outcome, there are two potential decisions to be made -(i) continue with the therapy, but increase the dosage of the ingredient, or (ii) switch to a different therapy.…”
Section: Measurement and Evaluation Of The Effect Of Active Ingredientsmentioning
confidence: 99%